BRANY Members Benefit from Streamlined Patient Payment System

August 11, 2011
Company News Release

BRANY (Biomedical Research Alliance of New York) research sites now have the opportunity to improve their patient stipend payments and manage their study budgets with a discount from Greenphire’s ClinCard System.

The ClinCard System is a fully configurable and primarily web-based technology, designed to comply with all applicable regulation and enabling sites and sponsors to deliver subject payments (stipends, travel reimbursements, and other ad-hoc payments) in a controlled and automated manner in compliance with industry regulation and in accordance with the specific requirements of each study.
“BRANY’s partnership with Greenphire is a natural extension of our suite of services to our alliance members,” says BRANY’s Carmela Houston-Henry, Director of Sales and Business Development. “Our members benefit from efficiency in managing their study budgets, and study participants receive expedited stipend payments.”

Recently Montefiore Medical Center, the University Hospital for Albert Einstein College of Medicine became the 100th study site to implement the ClinCard system. Montefiore joins a large and established base of sites and more than 20 sponsors and CROs in realizing the ClinCard’s benefits to the clinical trials process. By automating patient stipend payments, reimbursements, and communication through a web-based portal, Greenphire’s innovative technologies enhance the patient experience and improve patient retention, reduce administration associated with patient payments and communication for both site and sponsor users, and centralize reporting, tracking, and auditing of stipends and reimbursements.

The Biomedical Research Alliance of New York (BRANY) is a national organization providing support services to sponsors and investigators involved in research in a wide variety of therapeutic areas, medical devices, biologic and diagnostic trials. Staffed by multi-disciplinary experts, BRANY is an expedited "end-to-end solution" for clinical trials.